These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

601 related items for PubMed ID: 26464643

  • 1. Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells.
    Li N, Li H, Su F, Li J, Ma X, Gong P.
    Int J Clin Exp Pathol; 2015; 8(8):9010-20. PubMed ID: 26464643
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells.
    Li XY, Wu JZ, Cao HX, Ma R, Wu JQ, Zhong YJ, Feng JF.
    Oncol Rep; 2013 May; 29(5):1975-82. PubMed ID: 23440266
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.
    Tracy S, Mukohara T, Hansen M, Meyerson M, Johnson BE, Jänne PA.
    Cancer Res; 2004 Oct 15; 64(20):7241-4. PubMed ID: 15492241
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
    Li H, Schmid-Bindert G, Wang D, Zhao Y, Yang X, Su B, Zhou C.
    Adv Med Sci; 2011 Oct 15; 56(2):275-84. PubMed ID: 22037177
    [Abstract] [Full Text] [Related]

  • 9. p53 enhances gefitinib-induced growth inhibition and apoptosis by regulation of Fas in non-small cell lung cancer.
    Rho JK, Choi YJ, Ryoo BY, Na II, Yang SH, Kim CH, Lee JC.
    Cancer Res; 2007 Feb 01; 67(3):1163-9. PubMed ID: 17283151
    [Abstract] [Full Text] [Related]

  • 10. Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC).
    Gadgeel SM, Ruckdeschel JC, Heath EI, Heilbrun LK, Venkatramanamoorthy R, Wozniak A.
    J Thorac Oncol; 2007 Apr 01; 2(4):299-305. PubMed ID: 17409801
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer.
    Yang G, Yao Y, Zhou J, Zhao Q.
    Oncol Rep; 2012 Jun 01; 27(6):2066-72. PubMed ID: 22446631
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Radiosensitivity enhancement by combined treatment of celecoxib and gefitinib on human lung cancer cells.
    Park JS, Jun HJ, Cho MJ, Cho KH, Lee JS, Zo JI, Pyo H.
    Clin Cancer Res; 2006 Aug 15; 12(16):4989-99. PubMed ID: 16914589
    [Abstract] [Full Text] [Related]

  • 15. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
    Wu M, Yuan Y, Pan YY, Zhang Y.
    Mol Med Rep; 2014 Jun 15; 9(6):2417-22. PubMed ID: 24682085
    [Abstract] [Full Text] [Related]

  • 16. Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds.
    Huang Y, Chen Y, Mei Q, Chen Y, Yu S, Xia S.
    Oncol Rep; 2013 Jun 15; 29(6):2486-92. PubMed ID: 23525575
    [Abstract] [Full Text] [Related]

  • 17. Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells.
    Chen X, Zhou JY, Zhao J, Chen JJ, Ma SN, Zhou JY.
    Anticancer Drugs; 2013 Nov 15; 24(10):1039-46. PubMed ID: 23962905
    [Abstract] [Full Text] [Related]

  • 18. Epidermal growth factor signals regulate dihydropyrimidine dehydrogenase expression in EGFR-mutated non-small-cell lung cancer.
    Tominaga T, Tsuchiya T, Mochinaga K, Arai J, Yamasaki N, Matsumoto K, Miyazaki T, Nagasaki T, Nanashima A, Tsukamoto K, Nagayasu T.
    BMC Cancer; 2016 Jun 06; 16():354. PubMed ID: 27268079
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.
    Liu JT, Li WC, Gao S, Wang F, Li XQ, Yu HQ, Fan LL, Wei W, Wang H, Sun GP.
    Clin Lung Cancer; 2015 Sep 06; 16(5):e55-66. PubMed ID: 25979647
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.